Kate Rosenbluth is the CEO and Co-Founder of Cala Health. She is leading the team of innovators in a new class of therapy, neuroperipherals™, backed by the biggest leaders in technology and healthcare. Prior to Cala, she developed data-driven surgical, diagnostic and therapeutic technologies with Brainlab, Autonomic Technologies, Genentech, and UCSF. She has authored more than 50 patents and peer-reviewed publications and is a frequent speaker. She is a committed educator and has launched forward-looking programs including the Masters of Translational Medicine at UC Berkeley and the Accel Innovation Scholars at Stanford. She serves on the Strategy Group of the Center for Healthcare Innovation. She received a Mechanical Engineering Bachelors from Stanford University and a PhD in Bioengineering from UC Berkeley and UCSF, where she also completed a Postdoctoral Fellowship in Neurosurgery.
Kate Rosenbluth
